Afficher la notice abrégée

State of the Science on Brain Insulin Resistance and Cognitive Decline Due to Alzheimer’s Disease

dc.rights.licenseopenen_US
dc.contributor.authorRHEA, Elizabeth M.
dc.contributor.authorLECLERC, Manon
dc.contributor.authorYASSINE, Hussein N.
dc.contributor.authorCAPUANO, Ana W.
dc.contributor.authorTONG, Han
dc.contributor.authorPETYUK, Vladislav A.
dc.contributor.authorMACAULEY, Shannon L.
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorFIORAMONTI, Xavier
dc.contributor.authorCARMICHAEL, Owen
dc.contributor.authorCALON, Frederic
dc.contributor.authorARVANITAKIS, Zoe
dc.date.accessioned2024-08-20T10:29:59Z
dc.date.available2024-08-20T10:29:59Z
dc.date.issued2023-01-01
dc.identifier.issn2152-5250en_US
dc.identifier.urioai:crossref.org:10.14336/ad.2023.0814
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/201194
dc.description.abstractEnType 2 diabetes mellitus (T2DM) is common and increasing in prevalence worldwide, with devastating public health consequences. While peripheral insulin resistance is a key feature of most forms of T2DM and has been investigated for over a century, research on brain insulin resistance (BIR) has more recently been developed, including in the context of T2DM and non-diabetes states. Recent data support the presence of BIR in the aging brain, even in non-diabetes states, and found that BIR may be a feature in Alzheimer's disease (AD) and contributes to cognitive impairment. Further, therapies used to treat T2DM are now being investigated in the context of AD treatment and prevention, including insulin. In this review, we offer a definition of BIR, and present evidence for BIR in AD; we discuss the expression, function, and activation of the insulin receptor (INSR) in the brain; how BIR could develop; tools to study BIR; how BIR correlates with current AD hallmarks; and regional/cellular involvement of BIR. We close with a discussion on resilience to both BIR and AD, how current tools can be improved to better understand BIR, and future avenues for research. Overall, this review and position paper highlights BIR as a plausible therapeutic target for the prevention of cognitive decline and dementia due to AD
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.sourcecrossref
dc.subject.enBrain insulin resistance
dc.subject.enAlzheimer's disease
dc.subject.enType-2 diabetes mellitus
dc.subject.enInsulin receptor
dc.subject.enCognition
dc.title.enState of the Science on Brain Insulin Resistance and Cognitive Decline Due to Alzheimer’s Disease
dc.typeArticle de revueen_US
dc.identifier.doi10.14336/ad.2023.0814en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
bordeaux.journalAging and diseaseen_US
bordeaux.page0en_US
bordeaux.hal.laboratoriesNutriNeuro (Laboratoire de Nutrition et Neurobiologie Intégrée) - UMR 1286en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionBordeaux INPen_US
bordeaux.institutionINRAEen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcedissemin
hal.identifierhal-04673549
hal.version1
hal.date.transferred2024-08-20T10:30:02Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcedissemin
dc.rights.ccCC BYen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Aging%20and%20disease&rft.date=2023-01-01&rft.spage=0&rft.epage=0&rft.eissn=2152-5250&rft.issn=2152-5250&rft.au=RHEA,%20Elizabeth%20M.&LECLERC,%20Manon&YASSINE,%20Hussein%20N.&CAPUANO,%20Ana%20W.&TONG,%20Han&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
NutriNeuro_AgingDis_2024_Rhea.pdf
Taille:
1.597Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
914octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée